NeuBase Therapeutics, Inc. (NBSE)
Chart Events
Performance Outlook
| Previous Close | 0.8698 |
| Open | 0.8380 |
| Bid | 0.7900 x 1000 |
| Ask | 0.8190 x 800 |
| Day's Range | 0.7699 - 0.8380 |
| 52 Week Range | 0.6050 - 8.5340 |
| Volume | |
| Avg. Volume | 2,399,473 |
| Market Cap | 2.996M |
| Beta (5Y Monthly) | 0.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.2900 |
| Earnings Date | Dec 19, 2023 - Dec 26, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 140.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NBSE
Related Research
- NeuBase Therapeutics, Inc.Technical Assessment: Neutral in the Intermediate-TermAt the lows this week, the S&P 500 (SPX) fell right to the bottom of its bullish channel that started in October. In addition, the index hit the lower part of its very short-term channel off its late-July highs. With the market oversold and at support, it would not be surprising to see a counter-trend rally, but we are leaning toward a failed rally and then another leg lower.RatingFair ValueEconomic Moat3 days agoArgus Research
GlobeNewswireNeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023. “The NeuBase Board of Directors (“Board”) appreciates input from its shareholders. The Board remains committed to completing its comprehensive
PR NewswireSYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE
Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ: NBSE) ("Neubase"). Symetryx is now urging the Board to issue a special $1 per share dividend.
- GlobeNewswire
NeuBase Therapeutics to Explore Strategic Alternatives
PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that its Board of Directors (the “Board”) has completed a review of the Company’s business, including the status of its programs, resources, and capabilities. The Board has made the determination to halt further development of the Company’s pro
